ERBB2 and neoplasm: The use of tumor-specific biomarker signature profiles has been widely pursued in breast cancer based on early successful prognostic and therapeutic paradigms that relied on tumor stage and grade, as well as HER2, estrogen (ER), and progesterone (PR) receptor expression status.